Purpose. Surveillance of the bacterial spectrum and antibiotic-resistance patterns of locally occurring uropathogens is essential to serve as a basis for empirical treatment of urinary tract infections (UTIs), as antibiotic-resistance rates may vary geographically with significant differences between countries and regions, and with time.
INTRODUCTION
The use of antibiotics in healthcare inevitably leads to increasing antimicrobial resistance, with local antibiotic policies having a strong impact on resistance patterns [1] . In order to enhance patient health outcomes and reduce the emergence of resistance to antibiotics, coordinated strategies are needed [2] [3] [4] . It is essential to carry out surveillance of the bacterial spectrum and resistance to antibiotics of locally occurring uropathogens that could serve as a basis for empirical treatment of urinary tract infections (UTIs) and for surgical prophylaxis, as antibiotic-resistance rates may vary geographically, with significant differences between countries and regions, and with time [5] . The aim of this retrospective analysis was to assess the changes in the spectrum of bacteria cultured from urine samples of patients in Jahn Ferenc South Pest Teaching Hospital, Department of Urologyand to compare the annual change in bacterial antibiotic resistance.
METHODS
All urine samples (mid-stream urine, urine collected from catheterized patients and urine collected during urinary tract puncture) taken for any reason (including samples from patients having UTIs, as well as urine cultures taken preoperatively from asymptomatic patients not having UTIs) from inpatients in the department of urology in a tertiary care hospital in Hungary from January 2004 to December 2015 were retrospectively analysed. The Cochran-Armitage test was used to study the trends of antibiotic resistance and positive urine culture numbers. P<0.05 was considered significant.
To eliminate duplicate results, only one species per year per patient with an identical antibiogram was included in the statistical analysis. To describe the changes in resistance and bacterial spectrum, we used the following methods and simplifications: (1) resistance rates were discussed per antibiotic; (2) for presenting the changes in bacterial spectrum and resistance rates on tables and figures, we decided to include only the five most prevalent species present in >5 % of the bacterial spectrum; (3) in the cases of low numbers and high fluctuation of data, we displayed the mean occurrences of resistant isolates during consecutive years; (4) until 2010, we had limited data transferred from Corden International, microbiology laboratory, Budapestdue to the absence of an electronic database; therefore, missing data in table cells were marked as ND (not determined). The ND mark was also used in the cases of data not being determined based on the microbiologist's decision, mostly due to economic reasons.
From 2010, the improvement of our electronic computer system gave us the opportunity to perform data mining in depth. In order to evaluate the reason for increasing Klebsiella pneumoniae resistance, we were able to separate the extended-spectrum-b-lactamase (ESBL)-producing strains. Organisms that were able to hydrolyse third-generation cephalosporins, but could be inhibited by clavulanic acid (in vitro), were considered ESBL positive. However, isolates resistant to third-generation cephalosporins, yet sensitive to fourth-generation cephalosporins, were not considered as ESBL-producing organisms.
Culturing methods
For identification of the bacteria, the urine samples were collected in boric acid containers and sent to the microbiology laboratory. The inoculation of the pathogens was performed using a 0.01 ml loop into BD Brilliance UTI agar. After incubation at 37 C for 16-18 h in a normal atmosphere thermostat, the colonies were inoculated into OxoidColumbia blood or MacConkey agar (Oxoid). For identification of the micro-organisms, we used the BD Phoenix automated system (BD Biosciences) or ENTEROtest 16 kit (Lachema). There was no relevant change in methods nor antibiotics used for screening the resistance profile throughout the years. Until 2011, antibiotic-susceptibility testing was performed using the BD Phoenix automated system or Mueller-Hinton agar with the disc diffusion method in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines [6] , then we shifted to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) standards [7] . To determine MICs, the BD Phoenix automated system or Liofilchem MIC strips were used. After incubation, the isolates were classified as susceptible, intermediate and resistant according to the EUCAST MIC breakpoint tables [7] . In accordance with the international standards, Enterobacteriaceae were considered resistant to fosfomycin, colistin and tigecycline with MIC concentrations exceeding 32, 2 and 2 mg l
À1
, respectively.
Multi-drug resistant (MDR) species
Data for MDR species were gained from the report of Jahn Ferenc South Pest Teaching Hospitalto the Hungarian National Nosocomial Surveillance System (National Epidemiology Centre) [8] . In the report, species meeting the following criteria were considered MDR: vancomycin-resistant Enterococcus faecalis and Enterococcus faecium (VRE), ESBLproducing or carbapenem-resistant Enterobacteriaceae, MDR Pseudomonas aeruginosa (susceptible to 2 of the following antibiotics: piperacillin/tazobactam, ceftazidime, cefepime, imipenem, meropenem, ciprofloxacin, gentamicin, tobramycin, amikacin), carbapenem-resistant Acinetobacter baumannii, and different types of MDR Staphylococcus aureus including meticillin-resistant S. aureus (MRSA). 
RESULTS

Bacterial spectrum
Resistance patterns
The resistance rates for the antibiotics are summarized in Tables 1-6 .
Fluoroquinolones (Table 1)
Ciprofloxacin resistance in Escherichia coli showed a significant increase from 19 % (25/130) to 25 % (31/122) during the 12 years (P=0.021). In K. pneumoniae, resistance patterns against ciprofloxacin and norfloxacin fluctuated, varying between 26 % (7/27) to 59 % (17/29). In the case of Enterococcus faecalis, resistance to ciprofloxacin was above 47 % (22/47) and to levofloxacin exceeding 40 % (26/65). Pseudomonas aeruginosa showed variable, but significantly decreasing resistance to ciprofloxacin from 38 % (5/13) to 13 % (2/16), P=0.025, and levofloxacin, from 38 % (5/13) to 19 % (3/16), during the studied years (P=0.032). Resistance of Proteus mirabilis against ciprofloxacin varied between 10 % (2/20) and 44 % (7/16) in the second half of the studied period. 
Penicillin derivatives (
Carbapenems (Table 3)
No resistance developed to imipenem, meropenem and ertapenem in Escherichia coli, K. pneumoniae, Enterococcus faecalis and Proteus mirabilis during the examined years. Pseudomonas aeruginosa showed resistance rates with significant increasing tendency (P=0.026) versus imipenem, from 6 % (1/16) in 2010 to 27 % (4/15) in 2015; however, the increase from 0 % (0/16) to 19 % (3/16) in the case of meropenem was not significant (P=0.075) in the second half of the studied period.
Cephalosporins (Table 4)
Cephalosporin resistance was evaluated only for Gram-negative pathogens. Resistance to cefuroxime in Escherichia coli increased slightly but not significantly (P=0.88) from 8 % (9/107) to 12 % (15/122), peaking in 2011 at 18 % (19/108). In K. pneumoniae, resistance to cefuroxime varied between 24 % (10/42) and 60 % (18/30), and in Proteus mirabilis it was under 8 % (1/12).
Cefixime resistance in Escherichia coli remained under 14 % (15/106) and in Proteus mirabilis it was 0 % (0/20 in 2015). The resistance rate in K. pneumoniae showed a non-significant increase (P=0.765) from 29 % (6/21) to 48 % (10/21).
In the case of ceftriaxone and ceftazidime, Escherichia coli showed a slight but significant increase in resistance during the study years, from 1 % (1/129) to 8 % (10/122), and 0 % (0/156) to 8 % (10/122), respectively (P<0.0001 and P=0.015, respectively). In K. pneumoniae, resistance rates against ceftriaxone fluctuated between 24 % (10/42) and 57 % (17/30) in the second half of the period. No ceftriaxone and ceftazidime resistant Proteus mirabilis strain was cultured. Pseudomonas aeruginosa showed resistance to ceftazidime ranging from 0 % (0/20) to 16 % (3/19).
Cefepime resistance in Escherichia coli increased significantly (P<0.0001) from 1 % (1/129) to 8 % (8/103). The resistance level of K. pneumoniae reached 40 % (4/10) in 2012. Resistance rates found in the case of Pseudomonas aeruginosa and Proteus mirabilis for cefepime decreased from 15 % (2/13) to 6 % (1/16), and from 10% (1/10) to 0 % (0/16), respectively; however, the changes were statistically not significant (P=0.446 and P=0.331, respectively).
Aminoglycosides (Table 5 ) Gentamicin resistance remained under 7 % (10/140) in Escherichia coli. The resistance rates significantly decreased from 100 % (38/38) to 50 % (35/70) in Enterococcus faecalis (P<0.0001), 31 % (4/13) to 13 % (2/16) in Pseudomonas aeruginosa (P=0.011), and 30 % (3/10) to 15 % (3/20) in Proteus mirabilis (P=0.013), while in K. pneumoniae a significant increase (P<0.0001) was observed from 0 % (0/23) to 36 % (8/22).
Resistance to amikacin in Escherichia coli decreased significantly (P=0.003). In 2004, the resistance rate was 4 % (5/ 130), while in 2011, which was the last year that it was tested in larger numbers, the rate was 0 % (0/108). Resistance of Pseudomonas aeruginosa was 6 % (1/16) in 2015.
In the last year of testing, no resistance to amikacin was found in K. pneumoniae and Proteus mirabilis cultures.
Sulfamethoxazole/trimethoprim (Table 6a 2012. In the case of Proteus mirabilis, resistance rates ranged between 20 % (2/10) and 63 % (10/16).
Nitrofurantoin (Table 6a) Resistance to nitrofurantoin in Escherichia coli remained below 2 % (3/129). K. pneumoniae and Proteus mirabilis were 100 % (21/21 and 20/20, respectively) resistant to nitrofurantoin in 2015.
Fosfomycin (Table 6b ) Fosfomycin was tested in the laboratory between 2010 and 2012. We found relatively low resistance rates for Escherichia coli, 0 % (0/102) to 5 % (1/20); K. pneumoniae, 0 % (0/7) to 15 % (3/20); and Proteus mirabilis, 0 % (0/4) to 14 % (1/7).
Polymyxin B (Table 6b) Resistance to polymyxin B was 95 % (19/20) to 100 % (21/21) in Proteus mirabilis, and 0 % in Escherichia coli, K. pneumoniae and Pseudomonas aeruginosa, between 2010 and 2015 (in 2015 the rates were 0/122, 0/22 and 0/16, respectively).
Additional data
In Pseudomonas aeruginosa, resistance to colistin ranged between 0 % (0/16) and 8 % (1/13), and to tobramycin between 0 % (0/16) and 16 % (7/45). Piperacillin/tazobactam was tested with Pseudomonas aeruginosa with the highest rate of resistance in 2014 : 11 % (5/45). In Enterococcus faecalis, tigecycline and vancomycin resistances remained at 0 % (0/70 in 2015), but the tetracycline resistance level was high and ranged from 87 % (41/47) to 94 % (17/18).
MDR species (Table 7) Combined data on all MDR species is available only from 2013 and is presented in Table 7 (a). During this period, the rate of MDR bacteria showed a significant (P=0.008) increase from 8 % (23/279) to 14 % (42/305).
ESBL-producing K. pneumoniae and Escherichia coli (Table 7b 
DISCUSSION
The optimal treatment of hospitalized patients requires knowledge of the antimicrobial-resistance patterns of the most frequent uropathogens. It is extremely important to carry out surveillance of the regional and local spectrum of 
the most commonly occurring bacteria and antimicrobialresistance rates during empirical treatment [9, 10] .
The Global Prevalence of Infections in Urology (GPIU) study is an annual worldwide-performed point prevalence study intended to create surveillance data on antibiotic resistance, type of urogenital infections and risk factors, and data on antibiotic consumption in urological departments. According to the results of the GPIU study between 2003 and 2010, the most frequently occurring bacteria in Northern Europe (the region Hungary is part of) were Escherichia coli (36 %) and Enterococcus species (14 %) [11] . In Jahn Ferenc South Pest Teaching Hospital, Department of Urology, about half of the cultured bacteria were Escherichia coli. This percentage is higher than in Northern European countries as a whole and is closer to the Escherichia coli rate found in Southern European countries (55 %), and shows a slight decrease over the years. We found Enterococcus faecalis to be the second most frequently occurring species, and the prevalence has significantly increased during the years to 28 %. This increasing trend may be explained by the more widespread use of urinary foreign bodies and endourological practices, and should be considered when selecting antibiotics for empirical treatment.
International data on resistance rates concerning hospitalized urological patients are controversial. In the 2003-2010 GPIU study, no obvious increase in resistance for most antimicrobials was observed. However, Jahn Ferenc South Pest Teaching Hospital, Department of Urologyshowed a significant increasing trend in the resistance to some antimicrobials.
Resistance of Escherichia coli to ciprofloxacin increased significantly from 19 to 25 %. Although these rates are lower than the rates found in the GPIU study, they are still considered too high for empirical treatment. Resistance of K. pneumoniae to ciprofloxacin was also high, ranging between 26 and 50 %, in accordance with the international data. Resistance of Enterococcus faecalis against ciprofloxacin and levofloxacin was higher than 50 and 40 %, respectively, while regarding Pseudomonas aeruginosa resistance against ciprofloxacin reached a mean of 22 %. Based on these data, the use of fluoroquinolones cannot be recommended for empirical treatment of UTIs in our region.
For all cephalosporins, resistance in Escherichia coli remained under 20 %. This may be attributed to a change in our antimicrobial policy, which aimed to reduce the usage of cephalosporins and fluoroquinolones. Despite that, a significant increase of resistance was observed in the case of Escherichia coli against ceftriaxone (P<0.0001), ceftazidime (P=0.015) and cefepime (P<0.0001), up to 8 %. However, these three resistance rates above are still below the 10 % limit for empirical treatment. Resistance rates of K. pneumoniae against cephalosporins were very high, reaching 60 %.
Resistance to cefepime, a fourth-generation cephalosporin, reached 40 % in 2012. These data are in accordance with the international trends. These high resistance rates for K. pneumoniae can be explained by the high percentage of MDR ESBL-positive K. pneumoniae strains in the last few years. Therefore, cephalosporins can be a good empirical choice for treating Gram-negative UTIs, but should be avoided in settings where MDR bacteria are suspected. Since Enterococcus faecalis is considered to be resistant to cephalosporins, relatively high rates of Enterococcus faecalis need to be taken into account in the case of empirical treatment, especially if a foreign body is placed or found in the urinary tract. It is a surprising fact that Proteus mirabilis was 100 % susceptible (4/ to ceftriaxone and ceftazidime over a period of 12 years, which can be explained by the low number of Proteus mirabilis-positive cultures (mean 13 samples per year).
Although most pathogens showed none to minimal resistance against carbapenems, the highly significant increase in the case of Pseudomonas aeruginosa (from 6 % to 27 % for imipenem, P=0.026) is alarming. The GPIU study and other international studies also found the worldwide spread of carbapenem-resistant bacteria in urological departments a considerable problem [12] .
Resistance against sulfamethoxazole/trimethoprim, fosfomycin and nitrofurantoin was acceptable in the case of the most frequent bacteria (except for MDR K. pneumoniae) despite the fact that these antibiotics were used more frequently in the last few years to reduce the usage of fluoroquinolones and cephalosporins, at least in the less severe, uncomplicated cases. Therefore, they may still be effectively used to replace fluoroquinolones in non-empirical therapy of uncomplicated lower UTIs.
The use of gentamicin is generally less frequent in Jahn Ferenc South Pest Teaching Hospital, Department of Urology, due to its toxicity. Resistance was, therefore, acceptably low, except in K. pneumoniae where we found significantly increasing rates.
We observed a significant increase in the rate of MDR species from 8 to 14 %, (P=0.008). This is in line with the international trends. Since 2010, 24-33 % of cultured K. pneumoniae strains were ESBL positive. In 2012, the rate was even higher, reaching 60 %. The rate of ESBL-resistant Escherichia coli varied between 6 to 9 % in the last 6 years, but in 2011 it reached 15 %. The increase of MDR bacteria, especially the increasing antimicrobial resistance of K. pneumoniae, with the concurrent lack of novel antimicrobial agent development is alarming. The GPIU study found that 9 % of the patients hospitalized in urological clinics developed nosocomial UTIs, due mostly to MDR uropathogens. Therefore, in the case of a nosocomial UTI, empiric antibiotic treatment should be aimed against these MDR pathogens (e.g. carbapenems or b-lactams with antiPseudomonas activity). When choosing antibiotics for UTIs, we also have to consider that many of these antibiotic groups, like fluoroquinolones or cephalosporins, are associated with the increasing incidence of Clostridium difficile infections [13] .
Limitations
Our study had the following limitations. Until 2010, we had limited data transferred from the microbiology laboratory due to the absence of an electronic database. Since 2010, the incorporation of a computer system gave us the opportunity to analyse more data. As the presented data is based on the analysis of microbiological samples without clinical background information, the rate of asymptomatic bacteriuria or symptomatic UTI could not be calculated, which could introduce biases. Our analysis contained urine samples taken from catheterized patients, which might introduce bias to the interpretation of the results. In some cases, the culture was taken after several days of hospital exposure, reflecting a possible change in the collected bacteria toward hospital-acquired flora. Some antibiotics were not routinely tested by the microbiology laboratory; therefore, they were not included in our analysis. Available data for multi-drug resistance was based on criteria for the official Hungarian national nosocomial infection surveillance, which does not always match the international criteria. The statistical significance of changes in some cases, due to low numbers of bacteria, could not be measured correctly. Since K. pneumoniae is naturally resistant to ampicillin, the reported resistance rate of 88 % in 2005 (Table 2 ) is considered to be incorrect.
Conclusion
Since the local pathogen profile and antimicrobial susceptibility may vary geographically and temporally, knowledge of the local bacterial spectrum and susceptibility patterns is mandatory for the correct empiric treatment of UTIs. The surveillance of antimicrobial use is necessary for establishing an appropriate infection control program and antibiotic policy. We recommend decreasing unnecessary usage of fluoroquinolones and cephalosporins in our region, and recommend instead the prescription of antimicrobials with low potencies for collateral damage, especially in less severe cases.
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